Lymphocyte immune globulin, anti-thymocyte globulin (equine) - Biologic Drug Details

Summary for lymphocyte immune globulin, anti-thymocyte globulin (equine)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for lymphocyte immune globulin, anti-thymocyte globulin (equine)

Mechanism of Action	Antibody-Surface Protein Interactions
Physiological Effect	Increased T Lymphocyte Destruction Lymphocyte Function Alteration
Established Pharmacologic Class	Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for lymphocyte immune globulin, anti-thymocyte globulin (equine) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for lymphocyte immune globulin, anti-thymocyte globulin (equine) Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for lymphocyte immune globulin, anti-thymocyte globulin (equine) Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine)

Last updated: February 21, 2026

What is the current market landscape for equine-derived lymphocyte immune globulin (ATG)?

The global market for equine anti-thymocyte globulin (ATG) is driven by its use in transplant rejection prevention, graft-versus-host disease (GVHD) management, and aplastic anemia. As of 2022, the market size approximated $300 million, with expectations to grow at a compound annual growth rate (CAGR) of roughly 7% over the next five years. Growth factors include rising transplant procedures, expanding indications in autoimmune disorders, and increasing adoption in developing regions.

How does the competitive environment look?

The market comprises a few key players: -vány US-based Thermo Fisher Scientific and ATS Biologicals dominate through established manufacturing and regulatory approval.

• Several regional manufacturers and generics are present, especially in India and China.
• The biosimilar landscape remains limited due to production complexity and regulatory hurdles.

Market share distribution shows Thermo Fisher controlling approx. 40%, with the remaining divided among regional players.

What are the key drivers influencing market growth?

Increasing Transplant Procedures

Organ transplantation volumes have increased globally. Data from the Global Observatory on Donation and Transplantation (GODT) report a 12% rise in kidney transplants over the past five years. ATG is critical for immunosuppressive regimens in allograft survival.

Expanding Use in Autoimmune Disorders

ATG's off-label use in conditions such as multiple sclerosis and aplastic anemia has expanded. The approval of newer indications contributes to revenue growth.

Rising Demand in Emerging Markets

Healthcare infrastructure improvements and pertussis awareness in emerging markets boost transplant volumes. These regions show early-stage adoption potential.

Regulatory and Supply Chain Factors

Stringent regulations delay market entry for biosimilars, favoring established brands. Supply chain disruptions, notably during the COVID-19 pandemic, affected manufacturing and distribution, causing short-term revenue impacts.

What are the major challenges?

Manufacturing Complexity

ATG production involves obtaining hyperimmune serum from immunized horses, followed by purification. Variability in immunization protocols and serum collection impacts product consistency.

Safety and Immunogenicity Concerns

Equine proteins can induce serum sickness and hypersensitivity reactions. Safety profiles influence prescribing practices and market acceptance.

Regulatory Barriers

Stringent approval processes across jurisdictions delay market entry for biosimilars and new entrants, preserving market share among incumbents.

What is the projected financial trajectory?

Revenue Growth

Forecasted revenue from equine ATG is expected to grow from $300 million in 2022 to approximately $470 million by 2027. This reflects a CAGR of approximately 7.1%, aligned with historical growth rates.

Key Growth Segments

• Transplant rejection prophylaxis: 70% of sales
• Autoimmune disorder management: 20%
• Emerging markets: 10%, with potential for rapid growth owing to increasing transplant volumes

Profitability Trends

Gross margins for major players hover around 55-60%, constrained by manufacturing costs. R&D investments focus on improving safety and immunogenicity profiles, with a modest impact on margins.

Investment Outlook

Market participants focus on optimizing production efficiency and expanding indications. Companies investing in process innovations may gain a competitive advantage.

How do regulatory pressures impact the market?

The US Food and Drug Administration (FDA) classifies equine ATG as a biological product requiring extensive safety data and approval processes. Similar requirements exist in Europe and Asia. Biosimilar development faces hurdles, including demonstrating equivalence and managing immunogenicity risks, which prolongs time-to-market.

What are the implications of alternative agents?

Newer biologics, such as rabbit-derived ATG or synthetic immunosuppressants, potentially challenge the market by offering improved safety profiles or manufacturing efficiencies. Nonetheless, equine ATG remains the standard in many current regimens owing to proven efficacy and established safety in long-term data.

Summary table of market data

Parameter	2022 Estimate	2027 Projection	CAGR
Market size (USD)	$300 million	$470 million	7.1%
Major players' market share (%)	Thermo Fisher (40%)	—	—
Transplant rejection segment (%)	70	—	—
Autoimmune indication (%)	20	—	—

Key Takeaways

• The global equine ATG market is set for steady growth, driven by increased transplant activity and expanding autoimmune indications.
• Market dominance remains with a few large players, owing to manufacturing complexity and regulatory barriers.
• Supply chain resilience and innovation in safety profiles are critical to future profitability.
• The growth in emerging markets provides significant upside, contingent on healthcare infrastructure development.
• Biosimilar entrants face significant hurdles, limiting near-term competition.

FAQs

1. What factors most influence the growth of equine ATG?
Transplant procedure volumes, autoimmune disorder treatment adoption, and regional healthcare infrastructure improvements primarily drive growth.

2. How does manufacturing complexity impact market entry?
The difficulty in producing consistent, safe products limits biosimilar market penetration and favors established manufacturers.

3. What are the prevalent safety concerns with equine ATG?
Hypersensitivity reactions, including serum sickness, constrain product use in some patient populations.

4. Will biosimilar versions significantly impact market share?
Current regulatory and manufacturing hurdles restrict biosimilar penetration, but future innovations could alter this landscape.

5. Which regions offer the most growth potential?
Emerging markets like India and Southeast Asia have high growth potential driven by increasing transplant procedures and healthcare investments.

---

References

[1] Global Observatory on Donation and Transplantation. (2022). Organ transplant statistics. WHO.